Stockpiled Vaccine Can Be Recognized As Revenue In Next Fiscal Year, Says SEC
This article was originally published in The Pink Sheet Daily
Executive Summary
The "unique" nature of vaccines sold for stockpiling allows companies to record revenue without meeting traditional requirements, according to an SEC guidance.
You may also be interested in...
SEC Seeks Vaccine Manufacturer Input On Pediatric Stockpile Accounting
Securities & Exchange Commission regulations on revenue recognition are preventing childhood vaccine manufacturers from selling product to a government stockpile. Rep. Waxman declares support for a special exemption for vaccine makers.
Vaccine Stockpile For HHS May Be Delayed By SEC Regs
Accounting regulations hinder booking payments from HHS for products which firms stockpile themselves, Aventis VP Hosbach says. Industry may seek an SEC exemption or a change in the contract language from CDC.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.